Compare ADNT & PAHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADNT | PAHC |
|---|---|---|
| Founded | 2016 | 1946 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | N/A | 2014 |
| Metric | ADNT | PAHC |
|---|---|---|
| Price | $21.22 | $39.95 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 10 | 4 |
| Target Price | $23.10 | ★ $31.25 |
| AVG Volume (30 Days) | ★ 1.3M | 199.5K |
| Earning Date | 02-04-2026 | 02-04-2026 |
| Dividend Yield | N/A | ★ 1.24% |
| EPS Growth | N/A | ★ 288.74 |
| EPS | N/A | ★ 1.67 |
| Revenue | ★ $14,535,000,000.00 | $1,399,676,000.00 |
| Revenue This Year | $1.86 | $15.34 |
| Revenue Next Year | $2.20 | $3.28 |
| P/E Ratio | ★ N/A | $23.23 |
| Revenue Growth | N/A | ★ 33.72 |
| 52 Week Low | $10.04 | $16.16 |
| 52 Week High | $26.16 | $46.42 |
| Indicator | ADNT | PAHC |
|---|---|---|
| Relative Strength Index (RSI) | 51.31 | 51.36 |
| Support Level | $21.18 | $38.50 |
| Resistance Level | $22.45 | $39.91 |
| Average True Range (ATR) | 0.97 | 1.38 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 30.93 | 39.40 |
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.